Posts tagged ‘cancer research’
The breakthroughs that have revolutionized cancer treatment, transforming cancer in many cases to a very manageable and even curable disease, started out as just ideas.
“I will often tell patients there’s no therapy we’re using to help them that wasn’t derived from somebody’s idea in some laboratory, working late into the night,” said Stephen J. Forman, M.D., Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at City of Hope. “There’s a challenge, I think, maintaining a certain level of funding so that all good ideas get a chance to see if they’re going to help someone.”
The commitment to that ingenuity, along with the ability to seamlessly and safely bring those ideas from the laboratory to the patient, are what set City of Hope apart. The challenges in translating medicine into practical benefit, the future of precision medicine, how the field of cancer treatment has evolved and the role of 101-year-old City of Hope were the topics recently on “Charlie Rose,” a nationally syndicated show on PBS and Bloomberg television.
City of Hope President and Chief Executive Officer Robert W. Stone, Provost and Chief Scientific Officer Steven T. Rosen, M.D., and Forman sat down with Rose in an interview that aired Feb. 25. » Continue Reading
At City of Hope, innovative scientific research, important clinical studies and vital construction projects are all powered by philanthropy. Generous supporters fuel a powerful and diverse range of progress in science and medicine, enabling researchers and clinicians to improve cancer treatments and create cures not just for cancer, but also for diabetes and other life-threatening illnesses.
Take a look at what City of Hope supporters have helped build, launch and create over the past year:
Improving care through science
Innovative approaches: In 2014, John Williams, Ph.D., associate professor of molecular medicine, pushed ahead in his research on meditope technology. As described in the Proceedings of the National Academy of Sciences, these engineered peptides “fit” into antibodies, much like a lock and key, making it possible to selectively deliver material to cancer cells.
This research has already earned funding from the prestigious W. M. Keck Foundation, which is helping Williams’ team advance its applications. Those include the recent development of several new meditopes that can be attached to therapeutic antibodies targeting several different forms of cancer, including breast cancer. » Continue Reading
If you haven’t heard the term “precision medicine,” you will. If you don’t have an opinion about access to it, you will.
On Friday, President Barack Obama unveiled details of the Precision Medicine Initiative, an effort intended to accelerate cancer research in a powerful way, giving doctors new knowledge and new therapies to help them better treat individual patients much more effectively than is generally currently possible.
The specific goal of the $215 million plan is the creation of more targeted treatments for individual patients, not general-approach therapies that doctors then try to modify to the best of their abilities. As the White House said in a briefing:
“Most medical treatments have been designed for the ‘average patient.’ As a result of this ‘one-size-fits-all-approach,’ treatments can be very successful for some patients but not for others. This is changing with the emergence of precision medicine, an innovative approach to disease prevention and treatment that takes into account individual differences in people’s genes, environments and lifestyles. Precision medicine gives clinicians tools to better understand the complex mechanisms underlying a patient’s health, disease or condition, and to better predict which treatments will be most effective.”
Explaining a prostate cancer diagnosis to a young child can be difficult — especially when the cancer is incurable. But conveying the need for prostate cancer research, as it turns out, is easily done. And that leads to action.
Earlier this year, Gerald Rustad, 71, who is living with a very aggressive form of metastatic prostate cancer, found himself trying to explain his heath condition to 10-year-old granddaughter Aurora.
He told her that his cancer couldn’t be cured, but that scientists at City of Hope were busily conducting research so they could help patients like himself. His doctor, for example, Sumanta Pal, M.D., co-director of City of Hope’s Kidney Cancer Program, was working with other City of Hope researchers to develop a drug that could treat metastatic prostate cancer without targeting testosterone.
The targeting of testosterone is too arcane for most 10-year-olds, but the need for scientific answers isn’t. Aurora asked if there were any way she could help. » Continue Reading
Cancer cells are voracious eaters. Like a swarm of locusts, they devour every edible tidbit they can find. But unlike locusts, when the food is gone, cancer cells can’t just move on to the next horn o’ plenty. They have to survive until more food shows up — and they do.
Mei Kong, Ph.D., assistant professor in the Department of Cancer Biology, recently received $1.7 million from the National Cancer Institute to understand how cancerous cells survive their self-imposed famines.
Glutamine is an essential form of food for cancer cells. The amino acid provides the energy the cells need to survive and multiply. But malignant cells are gluttons and grow so rapidly they run through the glutamine stores, leaving themselves without their nutrition source. Although this should cause the cells to starve to death, it doesn’t.
Kong is working to uncover the tricks cancer cells use to stifle their hunger until the famine again turns to feast. So far she and her colleagues have found several proteins and molecular pathways involved in the process. The current grant will help them extend their studies, furthering our investment in scientific discovery to uncover possible new cancer therapies.
Thousands gathered at City of Hope on Sunday, Nov. 2, to participate in the 18th annual Walk for Hope, a unique event that raises money for, and awareness of, women’s cancers.
Together participants cheered, supported, honored and commemorated those who have been affected by breast and gynecologic cancers. With more than 600 survivors in attendance, the impact of City of Hope’s research and care was evident to all.
Walk for Hope is the only walk series that benefits research, treatment and education programs for all cancers unique to women, and all funds raised support City of Hope’s Women’s Cancers Program.
Most special about the walk is that it celebrates the collaboration between researchers, patients and the community to end women’s cancers. Further, it’s the only walk held on the grounds of an institution where the research occurs and where the care is delivered. Participants not only walked by buildings where the breakthroughs of tomorrow will be discovered, they walked by City of Hope Helford Clinical Research Hospital, waving to (and receiving waves from) patients watching from the windows.
“City of Hope’s specialized treatment of cancer, greater understanding of the causes of cancer and the research into survivorship after cancer have all been made possible by your support,” said Alexandra Levine, M.D., M.A.C.P., chief medical officer at City of Hope, addressing the crowd. “You help us with our research, and our research helps the world.”
Beverly Austin, a 16-year breast cancer survivor, shared her story during the opening ceremony, highlighting the community’s support and City of Hope’s care. “Because of people like you, I’m here today,” she said.
And because of people like Austin, every year, City of Hope hosts Walk for Hope so that we can one day live in a world without women’s cancers.
Cancer research has yielded scientific breakthroughs that offer patients more options, more hope for survival and a higher quality of life than ever before.
The 14.5 million cancer patients living in the United States are living proof that cancer research saves lives. Now, in addition to the clinic, hospital and laboratory, there is another front for the fight against cancer: The battle for funding to keep this research ongoing.
City of Hope joins the American Association for Cancer Research in support of the Rally for Medical Research on Capitol Hill on Thursday, Sept. 18. Hundreds of organizations and individuals – comprehensive cancer centers, research advocacy groups, clinicians, business leaders, survivors and others – are joining the call to members of Congress to make funding for the National Institutes of Health a priority and stop the chronic decline of public funding for science.
» Continue Reading
Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life.
However, much work remains to be done. On average, one American will die of cancer every minute of every day this year, according to the American Association for Cancer Research, which today released its annual Cancer Progress Report. Following a year that saw six new cancer drugs approved, an estimated 14.5 million cancer survivors living in the United States, and considerable research breakthroughs, now is the time to continue fueling lifesaving cancer research through investment in the National Institutes of Health, National Cancer Institute and other organizations and agencies devoted to cancer research.
While gains in cancer research have been impressive, the pace of progress has been slowed due to years of budget cuts at the NIH and NCI.
“Incredible strides have been made in advancing our understanding, enhancing prevention and improving therapy of cancer,” said Steven Rosen, M.D., provost and chief scientific officer at City of Hope and director of the Comprehensive Cancer Center. “To maintain momentum with the ultimate goal of maximizing cure of these devastating diseases, the necessary funds must be available.”
Hijacking the same sorts of viruses that cause HIV and using them to reprogram immune cells to fight cancer sounds like stuff of the future.
Some scientists believe that the future is closer than we think – and are now studying the approach in clinical trials at City of Hope. Immunotherapy is a promising approach for cancer treatment, and while the science is quickly advancing, the idea isn’t exactly new.
In the late 1800s – before much was known about the immune system – William Coley, M.D., a New York surgeon, noticed that getting an infection after surgery actually helped some cancer patients. So he began infecting them with certain bacteria, with positive results.
Today, doctors continue to seek ways to harness the immune system to fight disease. City of Hope researchers are examining immunotherapy techniques to treat some of the toughest cancers including gliomas, ovarian cancer and hematologic cancers. One especially promising approach is called adoptive T cell therapy.